SCHEMBL16058150

SCHEMBL16058150

CCCc1ccc(-c2ccnc(OC(=O)O)c2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MCL1 Q07820 1/20 0.38
▸ THRB P10828 3/20 0.38
▸ RARB P10826 3/20 0.36
▸ PLA2G1B P04054 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATG4B Q9Y4P1 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KLF5 Q13887 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ ACACB O00763 1/20 0.35
▸ ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057060 0.92 RARB (0.46) RARBKMT2AALDH1A1KDM4EHPGD
SCHEMBL16057947 0.89 SLC22A12 (0.39) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL16058685 0.84 LMNA (0.39) RAB9AKMT2AALDH1A1HPGDL3MBTL1
SCHEMBL16058834 0.83 CYP3A4 (0.42) PDE10ASMN1; SMN2NPC1RAB9ARARB
SCHEMBL16057745 0.83 CYP2D6 (0.49) SMN1; SMN2NPC1TP53RAB9ARARB
SCHEMBL16057423 0.82 CCNC (0.39) KMT2AALDH1A1KDM4EHPGDACACB
SCHEMBL14975894 0.82 PORCN (0.40) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL16056911 0.81 ACACB (0.35) KMT2AALDH1A1L3MBTL1ACACB
SCHEMBL16058089 0.79 RARB (0.39) SMN1; SMN2RAB9ARARBKMT2AALDH1A1
SCHEMBL16057936 0.78 KIF11 (0.40) SMN1; SMN2THRBKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 PDE10A 436/4885SMN1; SMN2 1880/4885NPC1 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback